title: Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
abstract: The effects of long-term monotherapy with terazosin, an alpha-1 blocker, on blood pressure, glucose tolerance, and serum lipid profiles were prospectively investigated in 53 hypertensive patients: 19 with normal glucose tolerance (NGT) and 34 with impaired glucose tolerance (IGT). The plasma glucose, serum lipids, fructosamine, and glycosylated hemoglobin A1c (HbA1c) levels were determined before and during long-term (6 months) therapy with terazosin. A 75-g oral glucose tolerance test was performed before and during long-term terazosin therapy. Significant falls in both systolic and diastolic blood pressure in both patient groups were maintained during the long-term therapy with terazosin. Neither fasting nor postglucose-load venous plasma glucose levels were altered in either group of patients, and diabetes mellitus did not develop in any patient with NGT during the study. There was no significant change in the insulinogenic index (delta IRI/delta BS at 30 minutes after glucose load) in either patient group. In patients with IGT, glucose intolerance was slightly improved with significant reductions in HbA1c and fructosamine during terazosin therapy. Serum total cholesterol (TC) and triglyceride levels were significantly decreased in patients with IGT. In addition, TC and low density lipoprotein (LDL) cholesterol were significantly decreased in patients with hypercholesterolemia (TC > 220 mg/dL). These results suggest that long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensive patients and terazosin seems to be an antihypertensive agent with beneficial effects for hypertensive patients with either dyslipidemia or impaired glucose metabolism.
authors.affiliation: Second Department of Internal Medicine, Yokohama City University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Shionoiri
authors.forename: E
authors.initials: E
authors.lastname: Gotoh
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Hata
authors.forename: H
authors.initials: H
authors.lastname: Iwatsubo
authors.forename: K
authors.initials: K
authors.lastname: Takegawa
authors.forename: T
authors.initials: T
authors.lastname: Ogihara
authors.forename: H
authors.initials: H
authors.lastname: Mikami
authors.forename: H
authors.initials: H
authors.lastname: Ikegami
authors.forename: A
authors.initials: A
authors.lastname: Otsuka
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D005947:Glucose; D011224:Prazosin